Holen Sie sich die Stockscreener-App
18.50
5.42%
-1.06
Handel nachbörslich:
18.70
0.20
+1.08%
Schlusskurs vom Vortag:
$19.56
Offen:
$19.59
24-Stunden-Volumen:
2.65M
Relative Volume:
0.94
Marktkapitalisierung:
$3.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-4.7927
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
-7.68%
1M Leistung:
-7.45%
6M Leistung:
+106.94%
1J Leistung:
-27.34%
1-Tages-Spanne:
$18.00
$19.79
1-Wochen-Bereich:
$18.00
$20.17
52-Wochen-Spanne:
$6.36
$26.18
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.50 | 3.22B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus - ts2.tech
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.7%What's Next? - MarketBeat
Liquidity Mapping Around (DYN) Price Events - Stock Traders Daily
Dyne Therapeutics (DYN) climbs 9.5% on stellar results for DMD therapy candidate - MSN
Dyne Therapeutics Earnings Notes - Trefis
Free cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Free cash flow per share of Dyne Therapeutics, Inc. – BOATS:DYN - TradingView — Track All Markets
CapEx per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Operating cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
First Week of February 2026 Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
DYN (Dyne Therapeutics) EV-to-OCF : -7.12 (As of Dec. 27, 2025) - GuruFocus
Why analysts see a huge upside for Dyne Therapeutics (DYN) - MSN
Dyne Therapeutics (DYN): Valuation Check After Board Addition Signals Next Phase of Commercial Growth - Sahm
Dyne Therapeutics appoints Vikram Karnani to board of directors By Investing.com - Investing.com Nigeria
Dyne Therapeutics Bets Big On Breakthrough Muscle Disease Treatments - Finimize
Dyne Therapeutics (DYN): Reaffirmed Buy Ratings Prompt Fresh Look at Valuation After Neuromuscular Data Update - Yahoo Finance
Dyne Therapeutics appoints Vikram Karnani to board of directors - Investing.com
Dyne Therapeutics Appoints Vikram Karnani to Board - TipRanks
Dyne Therapeutics appoints Vikram Karnani to board - MSN
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - The Manila Times
Dyne Therapeutics Appoints Vikram Karnani as Independent Director - TradingView — Track All Markets
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors to Support Commercialization Efforts - Quiver Quantitative
Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors - TradingView — Track All Markets
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) - Finviz
Dyne Therapeutics (DYN) Price Target Increased by 12.57% to 39.97 - Nasdaq
Dyne Therapeutics, Inc. $DYN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Understanding the Setup: (DYN) and Scalable Risk - news.stocktradersdaily.com
Will Dyne Therapeutics Inc. stock gain from government policiesTrade Analysis Report & Daily Oversold Stock Bounce Ideas - ulpravda.ru
How risky is Dyne Therapeutics Inc. stock nowJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber
Will Dyne Therapeutics Inc. stock reach all time highs in 2025Quarterly Trade Summary & Low Risk Profit Maximizing Plans - DonanımHaber
DYN (Dyne Therapeutics) EV-to-OCF : -6.50 (As of Dec. 19, 2025) - GuruFocus
Can Dyne Therapeutics Inc. stock deliver consistent earnings growth2025 Volatility Report & Safe Swing Trade Setup Alerts - DonanımHaber
Dyne to seek accelerated approval of DMD drug on Phase I/II data - MSN
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus - The Globe and Mail
Oppenheimer upgrades Dyne Therapeutics to outperform, raises target to $40 - MSN
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha
Evercore ISI Maintains and Lowers Price Target for Dyne Therapeu - GuruFocus
Dyne Therapeutics, Inc. (NASDAQ:DYN) Nasdaq Index Genetic Therapy Pathways - Kalkine Media
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Frazier Life Sciences Management L.P. Has $14.34 Million Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
TFG Asset Management GP Ltd Acquires New Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
Braidwell LP Has $31.16 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics offers to sell $300M in common stock - MSN
WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock - WilmerHale
Why Dyne Therapeutics stock was a big winner on Wednesday - MSN
Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) - The Globe and Mail
HighVista Strategies LLC Sells 52,096 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):